CD62L depleted donor lymphocyte infusion

CD62L depleted donor lymphocyte infusion (DLI) is a specialized cellular therapy used in the context of allogeneic hematopoietic stem cell transplantation (HSCT). This therapy involves collecting lymphocytes from the original stem cell donor, selectively depleting cells expressing CD62L (L-selectin), and infusing these modified cells into the transplant recipient[3]. CD62L is a marker found on naïve T-cells and central memory T-cells. The depletion of CD62L+ cells offers potential advantages by removing central memory T-cells which may cause mild graft-versus-host disease (GVHD), while retaining CD45RA+ effector memory T-cells (TEMRA)[3]. This selective depletion aims to reduce the risk of GVHD while preserving the beneficial graft-versus-leukemia (GVL) or graft-versus-tumor effects that help prevent disease relapse[3][4]. The therapy is typically administered after allogeneic HSCT to enhance immune reconstitution, reduce infectious complications, and prevent disease relapse[1][2][3]. Clinical studies have shown that CD62L depletion is highly efficient and appears safe without affecting engraftment, while providing TEMRA and effector memory T-cells to protect recipients against infections with a low risk of GVHD[3].

Other names

CD62L-depleted DLICD-62L-depleted DLICD 62L-depleted DLIL-selectin depleted T cellsnaive T-cell depleted DLI